Transcode Therapeutics, Inc. (RNAZ) Stock Price & Analysis

Transcode Therapeutics, Inc. (RNAZ) fell 4.41% to USD 2.06 as of September 8, 2026 at 06:54 UTC, according to Nexqual real-time market data.

RNAZ last closed at USD 2.06; the session ranged USD 2.05–2.18 on volume of 10,622 shares. Market capitalization is —, with a 52-week range of USD 1.83–20.99 (NCM). Source: Nexqual, September 8, 2026 at 06:54 UTC.

Key Statistics (as of September 8, 2026 at 06:54 UTC)

Technical Analysis (RNAZ)

Nexqual's technical model rates RNAZ "SELL" based on 2 bullish and 5 bearish signals across 128 daily candles, as of September 8, 2026 at 06:54 UTC.

From Transcode Therapeutics, Inc.'s Latest SEC 10-K Filing (filed 2026-04-15)

Key Strengths & Strategy (as disclosed to the SEC)

• Our Proprietary Delivery Engine, TTX, underpins multiple programs and is designed to (i) improve precision and targeting, (ii) enhance therapeutic index, and (iii) enable flexible payload and therapeutic modality development.
• The aggregate purchase price consisted of a cash subscription of $20 million paid on October 8, 2025, and a promissory note (the "Promissory Note") in the aggregate principal amount of approximately $5 million (together, the "Investment").
• Proprietary TTX Drug Design Engine The therapeutic potential of RNA in oncology remains an unrealized promise due, we believe, to the difficulty in safely and effectively delivering oligonucleotides to tumors.
• The aggregate purchase price comprised a cash subscription of $20 million and a promissory note (the "Promissory Note") in the aggregate principal amount of approximately $5 million (the "Investment").

Partnerships

• As consideration for the Unleash Licensing Agreement, pursuant to an Equity Issuance and Registration Rights Agreement with Unleash (the "Unleash Registration Rights Agreement"), we agreed to issue 1,136,364 shares of Series C Non-Voting Convertible Preferred Stock, par value $0.0001 per share, (the "Series C Preferred Stock") to Unleash.
• Concurrent with the Acquisition, we entered into an Investment Agreement (the "Investment Agreement") with DEFJ.

Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.

Peers & Related Stocks

Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: September 8, 2026 at 06:54 UTC. This page is informational and not investment advice.